rheumatic diseases

The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.

People Transfer

Premium

Fate Therapeutics names Ken Batchelor CSO; SV Life Sciences' Ross and MedImmune Ventures' Amprey join NKT Therapeutics board

NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.